INDIA –Cipla’s wholly-owned subsidiary, Cipla Health Limited (CHL), has signed a definitive agreement to acquire Endura Mass, a nutritional supplement brand in the category of weight gain from Medinnbelle Herbalcare Private Limited for an undisclosed amount.
Endura and all other associated trademarks would be part of the acquisition.
The company claims that this acquisition is in line with Cipla’s strategic imperative to augment the Company’s wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Endura Mass has been sold in India for 20 years to consumers actively looking to gain weight.
Cipla said the acquisition is in line with Cipla’s strategic imperative to augment the company’s wellness portfolio for bringing about a shift from an illness to a wellness mindset.
“With this strategic acquisition, we will be expanding our portfolio into a new category of weight gain, thereby catering to a very specific nutritional need for a set of our consumers,” said Shivam Puri, chief executive officer of CHL.
“Being underweight is linked to multiple challenges such as poor stamina, poor concentration and low immunity. The addition of Endura & Endura mass to our portfolio perfectly complements our existing offerings across all key wellness categories and would hence help us offer an even more comprehensive solution to all key consumer needs,” Puri added
India has approximately 20 million adults (male & female) population who are underweight.
Through this acquisition, Cipla Health Limited (CHL) will be in a position to build and develop the nutrition supplement category owing to its strong existing offline and online distribution muscle and a deep consumer insights engine.
The acquisition is subject to completion of certain closing conditions and CHL would immediately initiate distribution and marketing of the Endura Mass pending the closure of the proposed acquisition, the filing added.
Cipla claims that through this acquisition, CHL will is set in a position to build and develop the nutrition supplement category owing to its strong existing offline and online distribution muscle and a deep consumer insights engine, which has already helped create over 12 consumer health brands within the portfolio.
CHL is the consumer healthcare subsidiary of Cipla. It offers a diversified portfolio brands such as Nicotex, Cofsils, Prolyte ORS, Cipladine, MamaXpert, Maxirich, Naselin, Ciphands Clocip, Rivela Dermascience and Evexpert.
Cipla acquires minority stake in Achira Labs
Earlier, Pharmaceutical firm Cipla agreed to acquire a 21.05% stake in Achira Labs for 250 million Indian rupees (US$3.2 million), which is engaged in development and commercialization of point of care (PoC) medical test kits in India.
Bengaluru-based Achira is a medical diagnostics company and develops medical diagnostic products using microfluidic technology with an aim to bring sophisticated medical tests closer to the point of diagnosis, treatment and management.
In other news, Cipla Limited has agreed to acquire additional stake for Rs. 25.90 crore (US$3.3 million) in digital tech company GoApptiv Private Limited and post completion of the deal, Cipla’s total stake in GoApptiv will increase to 22.02% on a fully diluted basis.
The investment will be made in equity shares and Compulsorily Convertible Preference Shares and is likely to be completed within 30 days or such other date mutually agreed between the parties and shall be subject to fulfillment of necessary closing conditions.
The company’s earlier investment in GoApptiv in June 2020 has yielded growth and expanded Cipla’s channel reach across lower tier towns in India.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
